Why the study?
Effective therapies for HFpEF remain limited due to pathophysiological heterogeneity and incomplete understanding of underlying mechanisms, with the exact causal relationship between coronary microvascular dysfunction and HFpEF remaining unclear.
Design
Review
Authors
Loading...
Hypothesis-generating for microvascular-targeted therapies in HFpEF; prospective trials needed before clinical adoption.
Key points are not available for this paper at this time.
Velollari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: